Advances of the Nanotechnology in Targeted Nanomedicines for Treatment of Bone Cancers and Diseases
DOI:
https://doi.org/10.30683/1929-2279.2021.10.05Keywords:
Nanotechnology, Nanomedicine, Nanodrugs, Bone Cancer, Osteosarcoma, Bone Infection, Osteoarthritis, Targeted Delivery.Abstract
The ever-evolving field of nanotechnology has been applied over the years as an amazing potential tool in bone disorders through the development of targeted drug nanosystems. Bone diseases can be referred as any bone condition able to cause morbidity or even mortality to the host. Osteosarcoma has been most investigated condition for management and treatment by nanomedicine, and several nanomaterials such as nanoparticles, nanocapsules, nanospheres, nanodiamonds are being used for drug delivery. Likewise, other bone diseases, such as osteoporosis, osteonecrosis, osteoarthritis, bone tuberculosis have received nanotherapy with a large rate of success. The nanomedicine seems to make up a targeting lack by conventional therapy and chemotherapy, besides appointing to a trend of conservative clinical treatment, especially for severe disorders. Additionally, nanomedicine has advanced over the years, therefore, there is a strong need to accelerate its application in bone diseases reducing the mortality rate related to these conditions. This review article provides an overview on the advances of nanotechnology over the last two decades and highlights the pathways of investigations for targeted delivery nanoensembles.
Downloads
Published
Issue
Section
How to Cite
Similar Articles
- Maria Teresa Piccolo, Stefania Crispi, The Dual Role Played by p21 May Influence the Apoptotic or Anti-Apoptotic Fate in Cancer , Journal of Cancer Research Updates: Vol. 1 No. 2 (2012)
- Kamlesh Sodani, Amit K. Tiwari, Chun-Ling Dai, Alaa H. Abuznait, Atish Patel, Zhi-Jie Xiao, Charles R. Ashby, Amal Kaddoumi, Li-Wu Fu, Zhe-Sheng Chen, Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model , Journal of Cancer Research Updates: Vol. 3 No. 3 (2014)
- Leonello Tacconi, Gennaro D’acunzi, Raffaele Fristachi, Filippo Aquila, Osteosarcoma of Cervical Spine: Report of a Case Treated with Hadrontherapy , Journal of Cancer Research Updates: Vol. 7 No. 3 (2018)
- L.R. Morgan, R.S. Weiner, M.L. Ware, M. Bhandari, T. Mahmood, P. Friedlander, Early Phase I Results for 4-Demethyl-4-cholesteryloxypenclo-medine [DM-CHOC-PEN] as Therapy in Adolescent and Young Adult (AYA) Subjects with Advanced Malignancies , Journal of Cancer Research Updates: Vol. 7 No. 3 (2018)
- Parvin Mehdipour, Multi-Phase Based Signature and Cancer Management: An Insight in Embryo, Brain Tumor, Leukemia, and Von Hippel Lindau Syndrome , Journal of Cancer Research Updates: Vol. 12 (2023)
- Sh.R. Kzyrgalin, R.S. Yamidanov, A.A. Rizvanov, Sh.Kh. Gantsev, Antitumor Activity of Dehydroxymethylepoxyquinomicin (DHMEQ) in Monotherapy and Combination with Cisplatin in the SKOV-3 Ovarian Cancer Model , Journal of Cancer Research Updates: Vol. 13 (2024)
- Hossein Mozdarani, Zainab Kouchak Mashkdouz, The Potent Regulatory Role of Circular RNAs in Breast Cancer Development, Diagnosis and Treatment: An Update , Journal of Cancer Research Updates: Vol. 11 (2022)
- Caroline Page, Pierre-Alain Brioschi, Jacques Bernier, Short-Time Outcome of Intraoperative Radiotherapy (IORT): A Study on Side-Effects and Quality of Life in the Treatment of Early Breast Cancer , Journal of Cancer Research Updates: Vol. 2 No. 4 (2013)
- Abdul Lateef Ali Asghar, Anas K. Awn, Ban Hussein Ali, Nawras Khairi Fadhil, Youssef Shakuri Yasin, Assessing the Role of Bi- and Multi-Parametric MRI in Prostate Cancer-A Regional Study , Journal of Cancer Research Updates: Vol. 14 (2025)
- Yang-Hui Huang, Sung-Han Hsiao, Chung-Pu Wu, Isoreserpine Reverses Multidrug Resistance Mediated by ABCB1 , Journal of Cancer Research Updates: Vol. 4 No. 4 (2015)
You may also start an advanced similarity search for this article.